From: reuters.com Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain’s state-funded health service. The National Institute for Health and Care Excellence (NICE), the country’s cost-effectiveness agency, said on Thursday the two drugs were being recommended despite uncertainty about how long they extend overall …
-
-
Psyching Ourselves Out in a Positive Way as a Breast Cancer Survivor
-
My Home is My Haven for This Breast Cancer Survivor
-
As a Breast Cancer Survivor, There is Nothing Like Doing What You Love
-
The True Meaning of Easter
-
Peace for a Breast Cancer Survivor
